Growth Metrics

Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2026)

Spero Therapeutics posted quarterly Non-Current Debt of $91000.0 for Q1 2026, little changed on a QoQ basis from $91000.0 in Q4 2025.

Spero Therapeutics (SPRO) has 8 years of Non-Current Debt data on file, last reported at $91000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $91000.0; the trailing twelve-month figure through Mar 2026 stood at $91000.0 (changed N/A YoY), and the FY2025 full-year result was $91000.0, changed N/A from the prior year.
  • Non-Current Debt for Q1 2026 stood at $91000.0, roughly flat from $91000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $128000.0 in Q1 2022 and bottomed at $13000.0 in Q3 2024.
  • The 5-year median for Non-Current Debt is $87000.0 (2023), against an average of $77846.2.
  • The widest annual swing landed in 2023, when Non-Current Debt fell 9.38%; it then sank 79.03% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $96000.0 in 2022, then dropped by 9.38% to $87000.0 in 2023, then tumbled by 85.06% to $13000.0 in 2024, then soared by 600.0% to $91000.0 in 2025, then changed by 0.0% to $91000.0 in 2026.
  • The last three Non-Current Debt figures came in at $91000.0 (Q1 2026), $91000.0 (Q4 2025), and $13000.0 (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Spero Therapeutics 162.39 Mn 106.26 Mn - 91,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 91,000.00
Mar 31, 2026 91,000.00
Dec 31, 2025 91,000.00
Dec 31, 2025 91,000.00
Sep 30, 2024 13,000.00
Sep 30, 2024 13,000.00
Jun 30, 2024 25,000.00
Jun 30, 2024 25,000.00
Mar 31, 2024 38,000.00
Mar 31, 2024 38,000.00
Dec 31, 2023 87,000.00
Dec 31, 2023 87,000.00
Sep 30, 2023 62,000.00
Sep 30, 2023 62,000.00
Jun 30, 2023 72,000.00
Jun 30, 2023 72,000.00
Mar 31, 2023 85,000.00
Mar 31, 2023 85,000.00
Dec 31, 2022 96,000.00
Dec 31, 2022 96,000.00
Sep 30, 2022 107,000.00
Sep 30, 2022 107,000.00
Jun 30, 2022 117,000.00
Jun 30, 2022 117,000.00
Mar 31, 2022 128,000.00
Mar 31, 2022 128,000.00
Dec 31, 2021 138,000.00
Dec 31, 2021 138,000.00
Sep 30, 2021 148,000.00
Sep 30, 2021 148,000.00
Jun 30, 2021 158,000.00
Jun 30, 2021 158,000.00
Mar 31, 2021 168,000.00
Mar 31, 2021 168,000.00
Dec 31, 2020 177,000.00
Dec 31, 2020 177,000.00
Sep 30, 2020 186,000.00
Sep 30, 2020 186,000.00
Jun 30, 2020 196,000.00
Jun 30, 2020 196,000.00
Mar 31, 2020 205,000.00
Mar 31, 2020 205,000.00
Dec 31, 2019 249,000.00
Dec 31, 2019 249,000.00
Sep 30, 2019 256,000.00
Sep 30, 2019 256,000.00
Jun 30, 2019 293,000.00
Jun 30, 2019 293,000.00
Mar 31, 2019 312,000.00
Mar 31, 2019 312,000.00